-
1
The study analyzed adverse drug events (ADEs) for leflunomide, upadacitinib, and baricitinib using the FAERS database from January 2004 to December 2024.
-
2
Leflunomide, upadacitinib, and baricitinib reported 10,445, 27,433, and 2,638 ADEs respectively, with peaks in reports occurring in different years.
-
3
Baricitinib-related ADEs included infections and blood disorders, while leflunomide was associated with hepatic disorders and hereditary diseases.
-
4
Upadacitinib-related ADEs encompassed surgical and medical procedures, highlighting the distinct safety profiles of these RA treatments.
-
5
The study emphasizes the need for enhanced pharmacovigilance and early identification of ADEs to improve drug safety in rheumatoid arthritis management.
